Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models

• Published in: PloS one 2010-12, Vol.5 (12), p.e15482
• Main Authors: Kronik, Natalie, Kogan, Yuri, Elishmereni, Moran, Halevi-Tobias, Karin, Vuk-Pavlović, Stanimir, Agur, Zvia
• Format: Article
• Language: English
• Subjects: Algorithms; Analysis; Antigens; Applied mathematics; Calibration; Cancer; Cancer immunotherapy; Cancer therapies; Cancer treatment; Cancer Vaccines - therapeutic use; Cell adhesion & migration; Cell death; Cervical cancer; Computer simulation; Cytokines; Cytotoxicity; Data points; Dendritic cells; Drug dosages; Drug therapy; Feasibility studies; Humans; Immune system; Immunotherapy; Immunotherapy - methods; Lymphatic system; Lymphocytes; Male; Mathematical analysis; Mathematical models; Mathematics; Medical Oncology - methods; Medicine; Metastasis; Models, Theoretical; Patients; Phosphatase; Precision Medicine - methods; Predictions; Prognosis; Prostate - metabolism; Prostate cancer; Prostate-specific antigen; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms - immunology; Prostatic Neoplasms - therapy; Regulation; Regulatory approval; Retrospective Studies; Robustness (mathematics); T cell receptors; Training; Treatment Outcome; Vaccination; Vaccines
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0015482

Therapeutic vaccination against disseminated prostate cancer (PCa) is partially effective in some PCa patients. We hypothesized that the efficacy of treatment will be enhanced by individualized vaccination regimens tailored by simple mathematical models. We developed a general mathematical model encompassing the basic interactions of a vaccine, immune system and PCa cells, and validated it by the results of a clinical trial testing an allogeneic PCa whole-cell vaccine. For model validation in the absence of any other pertinent marker, we used the clinically measured changes in prostate-specific antigen (PSA) levels as a correlate of tumor burden. Up to 26 PSA levels measured per patient were divided into each patient's training set and his validation set. The training set, used for model personalization, contained the patient's initial sequence of PSA levels; the validation set contained his subsequent PSA data points. Personalized models were simulated to predict changes in tumor burden and PSA levels and predictions were compared to the validation set. The model accurately predicted PSA levels over the entire measured period in 12 of the 15 vaccination-responsive patients (the coefficient of determination between the predicted and observed PSA values was R(2) = 0.972). The model could not account for the inconsistent changes in PSA levels in 3 of the 15 responsive patients at the end of treatment. Each validated personalized model was simulated under many hypothetical immunotherapy protocols to suggest alternative vaccination regimens. Personalized regimens predicted to enhance the effects of therapy differed among the patients. Using a few initial measurements, we constructed robust patient-specific models of PCa immunotherapy, which were retrospectively validated by clinical trial results. Our results emphasize the potential value and feasibility of individualized model-suggested immunotherapy protocols.